COCH

Envoy Medical, Inc. (COCH) Economic Moat Analysis (2026)

Invetso Score: 2.3/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.4 (Weak)

COCH’s negative TTM ROIC and ROCE indicate it is not earning excess returns from proprietary brands, patents, or regulatory assets versus peers, which implies limited intangible-asset pricing power.

The absence of disclosed 5-year margin or return history in the provided metrics prevents evidence of durable premium economics, so any brand or IP advantage appears unproven relative to peers.

With no visible profitability uplift from intangibles, competitors likely can match offerings without COCH sustaining superior margins or retention, which weakens moat durability versus stronger branded or IP-protected peers.

Switching Costs

Score:

Negative ROIC alongside very low asset turnover suggests customers are not locked in by high integration or replacement costs, because the business is not converting capital into durable retained returns.

The provided metrics do not show recurring-margin stability or long-term profitability persistence, which implies switching frictions are not strong enough to preserve pricing power versus peers.

Compared with peers that benefit from embedded workflows, contractual lock-in, or mission-critical usage, COCH’s economics do not evidence meaningful customer dependence, so switching costs appear weak.

Network Effects

Score:

The available financial metrics do not show the scale-driven margin expansion or return profile typically associated with network effects, so there is no evidence of self-reinforcing user growth versus peers.

Negative capital returns indicate the business is not capturing increasing value from a growing ecosystem, which argues against a durable network advantage.

Unlike platform peers where more users improve product value and retention, COCH’s disclosed metrics do not support peer-dependent network strength, making this moat factor weak.

Cost Advantage

Score:

COCH’s negative ROIC and ROCE suggest it is not operating with a structural unit-cost edge that translates into superior after-tax returns versus peers.

The extremely low asset turnover implies capital intensity or underutilization rather than a lean cost structure, which reduces evidence of a durable cost advantage.

Because the provided data do not show sustained margin or return outperformance, peers likely can compete on price without COCH sacrificing a protected cost position.

Efficient Scale

Score:

The metrics do not indicate that COCH has reached a scale position where fixed costs are spread enough to deter entry or preserve superior returns versus peers.

Negative returns on capital imply scale is not currently translating into industry-level efficiency, which weakens the case for efficient-scale protection.

Compared with niche incumbents that can defend local or regulated markets through scale economics, COCH’s disclosed performance does not show a scarce-scale advantage.

Overall Score

Score:

COCH shows no evidence of a durable economic moat in the provided data, because negative capital returns and very low asset turnover do not support pricing power, retention, or structural cost advantages versus peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Envoy Medical, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →